Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TTOO Stock Forecast 2026-2027
$0.14
Current Price
$4.21M
Market Cap
Buy 3
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to TTOO Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
TTOO Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-50.0%
1 Year Change
0.0%
Year-to-Date Change
-97.9%
From 52W High of $6.80
+153.6%
From 52W Low of $0.06
📊 TOP ANALYST CALLS
Did TTOO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if T2 Biosystems is one of their latest high-conviction picks.
Latest TTOO Stock Price Targets & Analyst Predictions
TTOO has shown a year-to-date change of 0.0% and a 1-year change of -50.0%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for TTOO. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TTOO Analyst Ratings
3
Buy
2
Hold
0
Sell
TTOO Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.14
Latest TTOO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TTOO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 30, 2024 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $5.00 |
| Apr 29, 2024 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $3.00 |
| Jul 13, 2023 | Alliance Global Partners | Ben Haynor | Neutral | Maintains | $0.07 |
| Jan 24, 2023 | Alliance Global Partners | Ben Haynor | Neutral | Maintains | $1.50 |
| Oct 14, 2022 | Canaccord Genuity | Kyle Mikson | Hold | Downgrade | $2.50 |
| Jul 7, 2022 | Alliance Global Partners | Ben Haynor | Neutral | Downgrade | $N/A |
| Jul 7, 2022 | BTIG | Mark Massaro | Neutral | Downgrade | $N/A |
| Feb 18, 2022 | Alliance Global Partners | Buy | Upgrade | $N/A | |
| Jan 27, 2021 | Alliance Global Partners | Ben Haynor | Neutral | Downgrade | $2.40 |
| Jan 27, 2021 | SVB Leerink | Puneet Souda | Outperform | Maintains | $3.00 |
| Nov 5, 2020 | SVB Leerink | Outperform | Maintains | $4.00 | |
| Nov 5, 2020 | Canaccord Genuity | Buy | Maintains | $3.50 | |
| Oct 8, 2020 | BTIG | Buy | Initiates | $N/A | |
| Aug 12, 2020 | SVB Leerink | Outperform | Maintains | $3.00 | |
| Jul 16, 2020 | Canaccord Genuity | Max Masucci | Buy | Maintains | $4.00 |
| May 6, 2020 | SVB Leerink | Puneet Souda | Outperform | Reiterates | $2.00 |
| Nov 26, 2019 | Janney Capital | Neutral | Downgrade | $N/A | |
| Sep 12, 2019 | Janney Capital | Buy | Upgrade | $N/A | |
| Sep 12, 2019 | SVB Leerink | Outperform | Reiterates | $5.00 | |
| Aug 1, 2019 | Alliance Global Partners | Neutral | Downgrade | $0.40 |
T2 Biosystems Inc. (TTOO) Competitors
The following stocks are similar to T2 Biosystems based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
T2 Biosystems Inc. (TTOO) Financial Data
T2 Biosystems Inc. has a market capitalization of $4.21M with a P/E ratio of 0.0x. The company generates $7.68M in trailing twelve-month revenue with a -113.6% profit margin.
Revenue growth is +34.9% quarter-over-quarter, while maintaining an operating margin of -511.9% and return on equity of +178.6%.
Valuation Metrics
Market Cap
$4.21M
Enterprise Value
$20.02M
P/E Ratio
0.0x
PEG Ratio
-0.1x
Price/Sales
0.5x
Growth & Margins
Revenue Growth (YoY)
+34.9%
Gross Margin
-106.6%
Operating Margin
-511.9%
Net Margin
-113.6%
EPS Growth
+34.9%
Financial Health
Cash/Price Ratio
+69.7%
Current Ratio
0.4x
Debt/Equity
-1.6x
ROE
+178.6%
ROA
-84.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
T2 Biosystems Inc. (TTOO) Business Model
About T2 Biosystems Inc.
What They Do
Develops innovative diagnostics technology for healthcare.
Business Model
T2 Biosystems generates revenue by developing and commercializing advanced diagnostic products, primarily its T2 Magnetic Resonance (T2MR) technology. This technology enables rapid and accurate identification of pathogens, allowing healthcare providers to make timely treatment decisions, thus enhancing their services and operational efficiency.
Additional Information
The company is headquartered in Lexington, Massachusetts, and focuses on improving patient outcomes while reducing healthcare costs. Its technology is crucial for hospitals looking to enhance diagnostic speed and accuracy, particularly in the detection of bloodstream infections and Lyme disease.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
158
CEO
Mr. John J. Sperzel III, B.Sc.
Country
United States
IPO Year
2014
Website
www.t2biosystems.comT2 Biosystems Inc. (TTOO) Latest News & Analysis
Latest News
Quick Summary
T2 Biosystems extended its multi-year supplier agreement with Vizient through March 31, 2026, covering its sepsis detection products, including the T2Dx® Instrument and panels.
Why It Matters
The extension of T2 Biosystems' agreement with Vizient secures ongoing revenue and market presence, enhancing growth prospects and stability, which can positively influence investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The company plans to enhance the adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and establish a new royalty revenue stream.
Why It Matters
Accelerating adoption of whole-blood diagnostics can enhance market share and revenue, while non-dilutive capital and royalty streams improve financial stability and growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
T2 Biosystems, Inc. (NASDAQ:TTOO) will hold its Q3 2024 earnings conference call on November 14, 2024, at 4:30 PM ET, featuring key executives including the CEO and CFO.
Why It Matters
T2 Biosystems' upcoming earnings call will provide insights into financial performance and future strategies, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
T2 Biosystems, Inc. (NASDAQ:TTOO) will report Q3 2024 financial results and business updates on November 14, 2024, after market close.
Why It Matters
T2 Biosystems' upcoming financial report on November 14 may reveal insights into its performance and growth in the sepsis detection market, impacting stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
T2 Biosystems, Inc. (NASDAQ:TTOO) will hold a business update conference call on October 10, 2024, at 4:30 PM ET, featuring CEO John Sperzel and IR Trip Taylor.
Why It Matters
T2 Biosystems' upcoming conference call may reveal key insights on business performance and future strategies, impacting investor sentiment and stock price.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
T2 Biosystems (NASDAQ: TTOO) has signed a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH) for the sale of its FDA-cleared sepsis diagnostics.
Why It Matters
The exclusive agreement with Cardinal Health enhances T2 Biosystems' market reach, potentially boosting sales and revenue, which can positively impact stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TTOO Stock
What is T2 Biosystems Inc.'s (TTOO) stock forecast for 2026?
Analyst forecasts for T2 Biosystems Inc. (TTOO) are not currently available. The stock is trading at $0.14.
Is TTOO stock a good investment in 2026?
According to current analyst ratings, TTOO has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TTOO stock?
Price predictions from Wall Street analysts for TTOO are not currently available. The stock is trading at $0.14.
What is T2 Biosystems Inc.'s business model?
T2 Biosystems generates revenue by developing and commercializing advanced diagnostic products, primarily its T2 Magnetic Resonance (T2MR) technology. This technology enables rapid and accurate identification of pathogens, allowing healthcare providers to make timely treatment decisions, thus enhancing their services and operational efficiency.
What is the highest forecasted price for TTOO T2 Biosystems Inc.?
Price targets from Wall Street analysts for TTOO are not currently available. The stock is trading at $0.14.
What is the lowest forecasted price for TTOO T2 Biosystems Inc.?
Price targets from Wall Street analysts for TTOO are not currently available. The stock is trading at $0.14.
What is the overall TTOO consensus from analysts for T2 Biosystems Inc.?
The overall analyst consensus for TTOO is bullish. Out of 8 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell.
How accurate are TTOO stock price projections?
Stock price projections, including those for T2 Biosystems Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 5:16 PM UTC